Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Recruiting now Phase 2 NCT06990269
Run by ADARx Pharmaceuticals, Inc. · for 60 and older · All sexes
What this study is about
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Who can join (things the study team will check)
✅ You may be able to join if…
- Clinical diagnosis of GA of the macula secondary to AMD
- GA lesions between 2.5 and 12.5 mm2 at screening
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol
- Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol
🚫 You may not be able to join if…
- Has GA secondary to causes other than AMD
- Has active ocular disease that compromises or confounds visual function
- History of surgery for retinal detachment
- Has ocular condition other than GA secondary to AMD
- Use of intravitreal complement inhibitors in study eye
- Hereditary or acquired complement deficiency
- Active viral, bacterial or fungal infection
- Liver injury as evidenced by abnormal liver function tests
- Donating blood
- History of choroidal neovascularization in the study eye
Where this trial is running
- ADARx Clinical Site, Gilbert, Arizona, United States
- ADARx Clinical Site, Phoenix, Arizona, United States
- ADARx Clinical Site, Bakersfield, California, United States
- ADARx Clinical Site, Beverly Hills, California, United States
- ADARx Clinical Site, Huntington Beach, California, United States
- ADARx Clinical Site, Poway, California, United States
- ADARx Clinical Site, Orlando, Florida, United States
- ADARx Clinical Site, Wildwood, Florida, United States
- ADARx Clinical Site, Hagerstown, Maryland, United States
- ADARx Clinical Site, Reno, Nevada, United States
- ADARx Clinical Site, Erie, Pennsylvania, United States
- ADARx Clinical Site, Austin, Texas, United States
+ 15 more sites.
Who to contact
Nali Castillo · 877-232-7974 · info@adarx.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06990269.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.